mercoledì, 25 novembre 2020
6 Settembre 2018

FDA Grants LOXO-292 Breakthrough Designation for NSCLC, MTC

September 5, 2018 – The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC), according to Loxo Oncology, the manufacturer of the selective RET inhibitor. The breakthrough designation is specifically for the treatment of patients with metastatic RET fusion–positive NSCLC who require systemic therapy and have … (leggi tutto)